Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
281-300 of 1,738 trials

Bronchiectasis: Comparing Antibiotic Treatments for PA Infection

We are studying two antibiotic regimens to see which is more effective for adults with bronchiectasis and early Pseudomonas aeruginosa infections. This research may help improve treatment options for these patients.

Bronchiectasis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Cystic Fibrosis: VX-522 Treatment Study

We are testing a new medication, VX-522, for adults with cystic fibrosis who do not respond to current treatments. The study will help us understand its safety and effectiveness compared to existing therapies.

Cystic Fibrosis6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPulmonology

Advanced Solid Tumors: STX-478 Treatment Study

We are investigating the effects of STX-478 alone and with other cancer drugs for people with advanced solid tumors. This study aims to see how well these treatments work together.

Breast CancerAdvanced Solid TumorsHead and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)Oncology

Epcoritamab for Relapsed/Refractory Chronic Lymphocytic Leukemia

We are studying a new treatment called epcoritamab for patients with relapsed or refractory chronic lymphocytic leukemia and Richter's syndrome. The goal is to assess its safety and effectiveness, both alone and with other medications.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Heart Failure: JTT-861 Medication Study

We are evaluating a new medication, JTT-861, for individuals with heart failure with reduced ejection fraction. The study aims to see if it is safe and effective in improving heart function.

Heart Failure with Reduced Ejection FractionEfficacy phase (II)Investigational MedicinesCost ReimbursementCardiologyInternal Medicine

Advanced Solid Tumors: GRWD5769 Treatment Study

We are testing the safety and effectiveness of GRWD5769 alone and with cemiplimab in patients with advanced solid tumors. This study aims to find out how well these treatments work and their tolerability.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Fecal Microbiota Transplantation for Axial Spondyloarthritis

We are studying whether fecal microbiota transplantation can improve symptoms in patients with axial spondyloarthritis who haven't responded to standard treatments. This trial compares the effects of FMT to a placebo treatment.

Axial Spondyloarthritis>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteGastroenterologyRheumatology

Sotatercept for Children with Pulmonary Artery Hypertension

We are studying the safety and effects of sotatercept in children aged 1 to under 18 with pulmonary artery hypertension. This research aims to improve treatment options for young patients already receiving standard care.

Pulmonary Arterial Hypertension3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyPulmonology

Pediatric Cancer: Crizotinib Treatment Study

We are testing the safety and effectiveness of crizotinib, alone and with temsirolimus, for children with ALK, ROS1, or MET positive cancers. This study aims to find the best dose and understand how well these treatments work.

NeuroblastomaAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Dopaminergic Pathway Changes in Comatose Patients with Traumatic Brain Injury

We are studying how traumatic brain injuries affect dopamine pathways in patients who are in a coma. This research may help us understand recovery patterns and improve future treatments.

Traumatic Brain Injury>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesNeurologyOtolaryngology

Advanced Thyroid Cancer: Sacituzumab Govitecan Study

We are testing a new drug for patients with advanced differentiated and anaplastic thyroid neoplasms. The goal is to see if it can effectively control the disease and improve patient outcomes.

Thyroid Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Cystic Fibrosis: Long-Term Study of BI 3720931 Gene Therapy

We are monitoring the health of individuals with cystic fibrosis who previously received the BI 3720931 gene therapy. This study aims to assess the long-term safety and effectiveness of the treatment.

Cystic Fibrosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPulmonology

Prostate Cancer: 177Lu-PSMA Treatment Study

We are studying a new treatment for men with high-risk prostate cancer after initial therapies. The trial aims to see if this treatment helps prevent cancer from coming back and improves quality of life.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Dobutamine for Very Preterm Infants with Low Blood Flow

We are studying the lowest effective dose of dobutamine to help improve blood flow in very preterm infants. The trial also looks at how well the treatment works and its safety during the first few days after birth.

Neonates with Haemodynamic Insufficiency>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCardiologyPediatrics

Breast Cancer Treatment: Elacestrant with Olaparib

We are studying whether adding elacestrant to the standard treatment olaparib helps women with hormone receptor-positive, HER2-negative breast cancer and gBRCA1/2 mutations. This trial aims to improve progression-free survival and overall treatment outcomes.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Hematologic Malignancies: MK-1026 Treatment Study

We are evaluating a new treatment for patients with blood cancers to see if it is safe and effective in reducing symptoms. This study focuses on various types of hematologic malignancies, including CLL and MCL.

Blood CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Cancer Treatment: Imipramine for Fascin1 Overexpression

We are studying whether Imipramine can change tumor characteristics in patients with cancer that over-express a protein called Fascin1. This research may help us understand its effects on tumor behavior and markers.

Colon and Rectal Cancer3-6 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyOncology

Advanced Solid Tumors: AZD9574 Treatment Study

We are studying the safety and early effectiveness of AZD9574, both alone and with other cancer therapies, for patients with advanced solid tumors. This research aims to improve treatment options for those facing these challenging conditions.

Advanced Ovarian, Breast, Pancreatic, or Prostate CancerHER2+ Metastatic Solid TumorsAdvanced Unresectable or Metastatic Solid TumorsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Quizartinib for Pediatric FLT3-ITD Positive AML

We are studying the safety and effectiveness of quizartinib combined with chemotherapy in children and adolescents newly diagnosed with FLT3-ITD positive acute myeloid leukemia. This trial aims to see if it helps improve treatment outcomes compared to standard therapies.

Pediatric Acute Myeloid Leukemia (AML)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Prostate Cancer: New Treatment Combining Radiation and Antiandrogen

We are studying a new treatment approach for men with advanced prostate cancer to see if combining radiation therapy with a second-generation antiandrogen improves outcomes. The trial will also look at quality of life and any side effects from the treatment.

Oligometastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology